Navigation Links
Prohibited diet medicine found in Chinese herbs

According to researchers they have discovered fenfluramine, the diet medicine pulled from the market five years ago because it was linked to heart valve problems, in Chinese herbal remedies being sold to help people lose weight. According to reports of this study, there has been serious side effects, such as pulmonary hypertension, among a handful of patients led a group from Southend Hospital on Westcliff-on-Sea in Essex to study whether the supplements these patients// had taken contained any suspicious ingredients.Initially, researchers suspected Ephedra or Ma Huang, widely used in the United States and elsewhere in the world for weight loss but also linked to adverse side effects.

Instead, researchers found fenfluramine, a diet pharmaceutical that was part of the popular weight loss cocktail called "Fen-phen." Fenfluramine and dexfenfluramine were pulled from the market by the Food and Drug Administration in 1997 after numerous reports the off-label cocktail combo increased the risk of heart valve damage in the United States and also in the United Kingdom.

Researchers reported that high concentrations of fenfluramine were found in the Chinese supplements, researchers reported, and also in the patients' urine. The Medicines Control Agency, an investigative agency much in the United Kingdom similar to the FDA, is looking into where and when fenfluramine entered the supply chain.

Catherynn Conns, researcher and a biochemist, told that there are several changes needed to protect the public and also to protect reputable herbal practitioners themselves. Corns said there also is concern over the quality of the ingredients in some Chinese herbs. Some have been found to be adulterated with steroids and toxic heavy metals (such as lead and mercury) ... some of the pre-packaged pills imported from the Far East have not undergone rigorous quality control checks, and there is no certainty as to the actual contents.

Herbs used in
'"/>




Page: 1 2

Related medicine news :

1. Smoking to be Prohibited at Public Offices in Bangkok from 2008
2. Alternative medicine more popular among HIV positive patients
3. Complementary and Alternative medicine
4. Pharmacies in for a dose of bitter medicine
5. Magnetic resonance angiography in clinical medicine
6. Approaching through Telemedicine benefits patients
7. Spreading knowledge to doctors about herbal medicine
8. Diuretics are better for treating blood pressure problems than newer medicines
9. New medicine for ovarian cancer
10. Delay medicine for early epilepsy, says scientists
11. New dosage of medicine gets more results in neuroblastoma
Post Your Comments:
(Date:7/18/2008)...swire-USNewswire/ -- Two consumer,groups today fil... patent,on human embryonic stem cells held by the ...sumer Watchdog, formerly The Foundation for Taxpay...dation appealed to the U.S. Patent,Office,s Board ...rowed,WARF,s patent after the two groups requested...
(Date:7/18/2008)... within one hour before they undergo spinal surger...after the surgery, suggests a Johns Hopkins study ...Infectious Disease Journal (also available online...s outside of the golden one-hour window were three...ections at the surgery site, researchers report, p...
(Date:7/18/2008)...ptoms, but old drug offers new hope , , ... forward, one step back in the search for treatmen... studies in the July 19 issue of The Lancet , an ...lzheimer,s symptoms. But in a second report, a onc...ion of Alzheimer,s -- even though it cleared demen...
(Date:7/18/2008)...University of Pennsylvania School of Medicine have...ith familial Alzheimer,s disease disrupt the flow ...called PS1 and PS2 (presenilin 1 and 2), interact ... cell compartment. , "The ,calcium dysregulation...lzheimer,s disease has been suggested by previous ...
Breaking Medicine News(10 mins):Health News:Consumer Groups File Appeal on Challenge of Human Stem Cell Patent Held By WARF 2Health News:Averting postsurgical infections in kids: Give antibiotics within hour before first incision 2Health News:Alzheimer's Research Brings Progress, Setbacks 2Health News:Alzheimer's Research Brings Progress, Setbacks 3Health News:Alzheimer's Research Brings Progress, Setbacks 4Health News:Calcium may be the key to understanding Alzheimer's disease 2Health News:Calcium may be the key to understanding Alzheimer's disease 3
...ed by doctors and dentists according to a report r...rowa€?s Furness General Hospital is rated as good ...undly criticised the NHS services in Cumbria. The ... conducted by it is far more wide-ranging and toug...
...e neo-natal intensive care unit of the Rizal Medic...//effect was passed by the Philippine Health Secre...death of seven new born babies. The unfortunate d...rtified by the hospital to have occurred due to un...
...phenomenal rise in sexually transmitted diseases i...f the most common treatable sexually transmitted d...d to have increased four-fold in its incidence rat...ith new cases having been reported in both older a...
...erous, more so because its look and perception spe...lt’ status, and is becoming the life of many parti...that the hookah or the pipe is indeed a wolf in sh...redo, director of the Cancer Genetics and Epidemio...
Other Medicine News:Health News:Sexually Transmitted Diseases Soaring Due To Unsafe Sex 2
(Date:7/16/2008)... Raptor to Support Phase 2a Clinical Trial at UCSD...-- Raptor,Pharmaceuticals Corp. ("Raptor" or the "...ced the execution of a collaboration agreement (th...San Diego ("UCSD") to,include a Phase 2a clinical ... cysteamine bitartrate ("Cysteamine") in adolescen...
(Date:7/15/2008)... Fund Completion of Phase III Trials of Light Infu...tatic Colorectal Cancer and Phase I/II a... BELLEVUE, Wash., July 15 /- Light S...pany developing Light Infusion Therapy(TM),(Litx(T...nounced that it,has raised $40.1 million in a Seri...
(Date:7/15/2008)...Reports 92 Percent Response Rate to Combination Tr...ll/ -- Cephalon, Inc. (Nasdaq:,CEPH) announced tod...in the,Journal of Clinical Oncology, 92 percent of... cell non-Hodgkin,s lymphoma (NHL) responded to tr...e) for Injection plus rituximab.,This combination ...
(Date:7/14/2008)... VIEW, Calif., July 14 /- M...nounced it has initiated its,Phase 3 clinical prog...or,migraine., MAP0004 is orally inhaled and self-...oprietary Tempo(R) inhaler. In the company,s prior...ief in as fast as 10 minutes,with relief sustaine...
Breaking Medicine Technology:Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 2Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 3Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 4Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 5Light Sciences Oncology Raises $40.1 Million in Series C Financing 2Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 2Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 3Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 4Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 5MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 3MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 4Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 1Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 2Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 1AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 2AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 4American Chemical Societys Weekly PressPac Feb 6 2008 11486 1American Chemical Societys Weekly PressPac Feb 6 2008 11486 2American Chemical Societys Weekly PressPac Feb 6 2008 11486 3American Chemical Societys Weekly PressPac Feb 6 2008 11486 4American Chemical Societys Weekly PressPac Feb 6 2008 11486 5American Chemical Societys Weekly PressPac Feb 6 2008 11486 6American Chemical Societys Weekly PressPac Feb 6 2008 11486 7American Chemical Societys Weekly PressPac Feb 6 2008 11486 8American Chemical Societys Weekly PressPac Feb 6 2008 11486 9FindCareHomes com Features New Interactive Tools and Free Services to Simplify the Search for Elder Home Care 11484 1FindCareHomes com Features New Interactive Tools and Free Services to Simplify the Search for Elder Home Care 11484 2
...ne 4, 2007 – Data presented,today at this ye...ASCO) meeting in Chicago show that a novel combina...uorouracil (5-FU) therapy UFT,(tegafur–uraci...ponse rate in the first-line treatment of metastat...(Study of CPT-11 with Oxaliplatin combined,with UF...
...ne 4, 2007 – Genta,Incorporated (Nasdaq: GNT...ase 2 clinical trial of its marketed product, Gani...b (Rituxan®;,Genentech/IDEC) and dexamethasone...in’s lymphoma (NHL). The data were,presented...Clinical,Oncology (ASCO) in Chicago, IL. , ,Previo...
Other Medicine Technology:Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 2Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
Medicine Products: